ExodusPoint Capital Management LP Takes Position in Tempus AI, Inc. (NASDAQ:TEM)

ExodusPoint Capital Management LP bought a new stake in shares of Tempus AI, Inc. (NASDAQ:TEM - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 56,743 shares of the company's stock, valued at approximately $1,916,000.

Other institutional investors also recently added to or reduced their stakes in the company. Farther Finance Advisors LLC acquired a new stake in shares of Tempus AI in the 4th quarter worth approximately $34,000. Prestige Wealth Management Group LLC raised its holdings in Tempus AI by 910.4% during the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company's stock worth $36,000 after purchasing an additional 965 shares in the last quarter. First Horizon Advisors Inc. lifted its position in Tempus AI by 207.9% in the fourth quarter. First Horizon Advisors Inc. now owns 1,641 shares of the company's stock worth $55,000 after purchasing an additional 1,108 shares during the period. FNY Investment Advisers LLC bought a new position in Tempus AI during the 4th quarter valued at $67,000. Finally, IFP Advisors Inc acquired a new position in shares of Tempus AI during the 4th quarter valued at $76,000. Institutional investors and hedge funds own 24.22% of the company's stock.

Tempus AI Stock Performance

NASDAQ TEM traded up $1.83 during trading on Friday, hitting $42.12. 8,540,487 shares of the company traded hands, compared to its average volume of 5,511,880. Tempus AI, Inc. has a 12 month low of $22.89 and a 12 month high of $91.45. The business has a fifty day simple moving average of $56.19 and a 200 day simple moving average of $50.92. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55.

Remove Ads

Insider Transactions at Tempus AI

In related news, Director Nadja West sold 809 shares of the stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $51.11, for a total transaction of $41,347.99. Following the completion of the sale, the director now owns 37,705 shares in the company, valued at $1,927,102.55. This represents a 2.10 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Eric P. Lefkofsky sold 3,240,234 shares of Tempus AI stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $58.75, for a total value of $190,363,747.50. Following the completion of the transaction, the chief executive officer now directly owns 4,895,589 shares in the company, valued at approximately $287,615,853.75. This represents a 39.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 5,581,969 shares of company stock worth $316,538,582.

Analyst Ratings Changes

Several equities analysts have recently weighed in on TEM shares. Guggenheim restated a "buy" rating on shares of Tempus AI in a research report on Tuesday, February 25th. Bank of America raised their target price on shares of Tempus AI from $54.00 to $60.00 and gave the stock a "neutral" rating in a report on Monday, March 3rd. Loop Capital decreased their target price on shares of Tempus AI from $57.00 to $52.00 and set a "buy" rating for the company in a report on Tuesday, January 14th. Wolfe Research lowered shares of Tempus AI from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 26th. Finally, Morgan Stanley raised their price objective on shares of Tempus AI from $50.00 to $60.00 and gave the stock an "overweight" rating in a research note on Thursday, March 6th. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat.com, Tempus AI presently has a consensus rating of "Moderate Buy" and a consensus target price of $61.18.

Tempus AI Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.